Xinrong Ma Selected Research

AH 23848

1/2014	Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties.
9/2009	Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function.
3/2006	Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xinrong Ma Research Topics

Disease

21	Neoplasms (Cancer) 08/2021 - 06/2002
17	Neoplasm Metastasis (Metastasis) 01/2019 - 10/2005
16	Breast Neoplasms (Breast Cancer) 01/2019 - 01/2004
2	Ductal Carcinoma 01/2015 - 01/2014
1	Adenocarcinoma 08/2021
1	Warts (Wart) 08/2021
1	Stomach Neoplasms (Stomach Cancer) 08/2021
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021
1	Hypersensitivity (Allergy) 01/2020
1	Triple Negative Breast Neoplasms 01/2017
1	Cicatrix (Scar) 09/2014
1	Hemangioma (Angioma) 09/2014
1	Dehydration (Water Stress) 11/2008

Drug/Important Bio-Agent (IBA)

8	Prostaglandin E Receptors (Prostaglandin E Receptor)IBA 01/2017 - 03/2006
7	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2017 - 03/2006
4	Chemokine ReceptorsIBA 01/2019 - 08/2006
4	InterferonsIBA 01/2019 - 06/2002
4	ProstaglandinsIBA 01/2017 - 10/2006
3	Dinoprostone (PGE2)FDA Link 01/2017 - 02/2012
3	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2014 - 01/2004
3	AH 23848IBA 01/2014 - 03/2006
3	frondoside AIBA 01/2014 - 02/2012
3	Small Interfering RNA (siRNA)IBA 01/2014 - 09/2009
3	Prostaglandins EIBA 04/2012 - 03/2006
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2017
2	Protein Isoforms (Isoforms)IBA 01/2019 - 01/2015
2	Indomethacin (Indometacin)FDA LinkGeneric 01/2014 - 10/2005
2	LigandsIBA 03/2009 - 10/2005
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 10/2002 - 06/2002
2	RetinoidsIBA 10/2002 - 10/2002
1	Docetaxel (Taxotere)FDA Link 08/2021
1	Biomarkers (Surrogate Marker)IBA 08/2021
1	Dual OxidasesIBA 08/2021
1	Cisplatin (Platino)FDA LinkGeneric 08/2021
1	TESIBA 01/2021
1	venetoclaxIBA 01/2021
1	Immunologic Factors (Immunomodulators)IBA 01/2021
1	Cycloheximide (Cicloheximide)IBA 01/2020
1	CXC ChemokinesIBA 01/2019
1	15-hydroxyprostaglandin dehydrogenaseIBA 01/2017
1	Phenobarbital (Luminal)FDA Link 01/2017
1	Monoclonal AntibodiesIBA 02/2016
1	Aldehyde DehydrogenaseIBA 01/2014
1	EP4 Subtype Prostaglandin E ReceptorsIBA 01/2014
1	Adenylyl Cyclases (Adenylyl Cyclase)IBA 01/2013
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2013
1	Progesterone Receptors (Progesterone Receptor)IBA 02/2012
1	CytokinesIBA 02/2012
1	Estrogen ReceptorsIBA 02/2012
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2012
1	6-isopropoxy-9-oxoxanthene-2-carboxylic acidIBA 10/2010
1	Messenger RNA (mRNA)IBA 10/2010
1	Interferon-gamma (Interferon, gamma)IBA 09/2009
1	Abscisic AcidIBA 11/2008
1	Chemotactic FactorsIBA 07/2007
1	Chemokine CXCL9IBA 07/2007
1	Hormones (Hormone)IBA 10/2006
1	N- (1- (3- (4- ethoxyphenyl)- 4- oxo- 3,4- dihydropyrido(2,3- d)pyrimidin- 2- yl)ethyl)- N- pyridin- 3- ylmethyl- 2- (4- trifluoromethoxyphenyl)acetamideIBA 08/2006
1	ChemokinesIBA 08/2006
1	4- (4- cyano- 2- (2- (4- fluoronaphthalen- 1- yl)propionylamino)phenyl)butyric acidIBA 03/2006
1	Histocompatibility Antigens Class IIBA 10/2005
1	Celecoxib (Celebrex)FDA Link 10/2005
1	Therapeutic UsesIBA 10/2005
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 10/2005
1	hydrogen sulfite (bisulfite)IBA 01/2004
1	EnzymesIBA 01/2004
1	Thioredoxin-Disulfide ReductaseIBA 10/2002
1	Interferon-betaIBA 10/2002

Therapy/Procedure

3	Therapeutics 01/2021 - 10/2002
2	Radiotherapy 08/2021 - 09/2014
2	Transplantation 01/2014 - 01/2004
1	Local Anesthesia 09/2014
1	Oral Administration 01/2013
1	Immunotherapy 07/2007